GenMark Diagnostics, Inc.
$163.4K 8 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Neos Therapeutics, LP
Neos Therapeutics, LP reported $163,635.99 across General Payments, Research, and Ownership to 7,979 physicians and teaching hospitals across 7,979 transactions.
- $163.6K Below-median payer
- All-tracks total
- 7,979 Top quartile volume
- Transactions
- 7,979 Top quartile reach
- Recipients
- −$109.8K
- General Payments vs PY2023
Neos Therapeutics, LP reported $163,635.99 across all CMS Open Payments tracks (General + Research + Ownership) to 7,979 physicians and teaching hospitals in Program Year 2024 - ranking #1061 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $163,635.99, averaging $20.51 per recipient.
Neos Therapeutics, LP's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
50/100
Total payments
F
11/100
Transaction volume
C
68/100
Physician reach
C
71/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer neos-therapeutics-lp Neos Therapeutics, LP
$163.6K · #1061/1,925 · 0.0% industry · PY2024
- TOT $163.6K
- RANK #1061
- SHARE 0.0%
- TXN 7,979
- RCP 7,979
- CAT 4
- GEN $163.6K
- ΔGEN −$109.8K
- TOP1 12.1%
- PY 2024
Volume peers
Nearest volume peer: GenMark Diagnostics, Inc. ($163.4K)
Neos Therapeutics, LP sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Neos Therapeutics, LP's CMS-reported General Payments decreased by $109.8K (−40.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NEOS THERAPEUTICS, LPPY2023: NEOS THERAPEUTICS, LPPY2024: Neos Therapeutics, LP. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $273,436.23
- PY2024
- $163,635.99
What the Data Shows for Neos Therapeutics, LP
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Neos Therapeutics, LP that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $134.5K, accounting for 82.2% of this company's General Payments and 7,953 transactions.
General Payment Breakdown by Type
Across 4 types of general payments, Neos Therapeutics, LP's largest category was "Food and Beverage" at $134.5K - 82.2% of General Payments.
Neos Therapeutics, LP reports 4 general-payment categories - the top three are Food and Beverage (82.2%), Compensation for Services Other Than Consulting (16.0%), and Consulting Fee (1.0%). The remaining 1 category make up 0.8% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Neos Therapeutics, LP divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $134.5K | 7,953 | 82.2% |
| Compensation for Services Other Than Consulting | $26.1K | 19 | 16.0% |
| Consulting Fee | $1.7K | 3 | 1.0% |
| Travel and Lodging | $1.3K | 4 | 0.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $30,903.53 (18.9%) of $163,635.99 in this company's General Payments records across 3,679 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Neos Therapeutics, LP
The five named recipients with the highest reported General Payments from this company
- 1
Michael Feld
$19,793.95 across 36 reported transactions
- 2
George Bright
$4,292.14 across 9 reported transactions
- 3
Joseph Gagnon
$3,686.18 across 36 reported transactions
- 4
Benjamin Epstein
$2,311.44 across 11 reported transactions
- 5
David Ganeles
$819.82 across 41 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Neos Therapeutics, LP ranks #1061 of 1,925 by total payments (bottom 45% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,600 of 1,838 by HHI (bottom 13% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- National Marrow Donor Program : $4.2M total payments, HHI 169
- Dexcom, Inc. : $2.9M total payments, HHI 168
- Gilead Sciences, Inc. : $39.6M total payments, HHI 168
- Catalyst Pharmaceuticals, Inc. : $1.1M total payments, HHI 167
- Organogenesis Inc. : $2.1M total payments, HHI 167
- Sensus Healthcare, Inc. : $4.7K total payments, HHI 165
- Neos Therapeutics, LP (this company) : $163.6K total payments, HHI 165
- PureLife, LLC : $214.1K total payments, HHI 165
- Alexion Pharmaceuticals, Inc. : $12.5M total payments, HHI 164
- Titan Surgical Group, Llc : $40.3K total payments, HHI 164
- Polaris Technology Solutions LLC : $39.0K total payments, HHI 164
- Ambu Inc. : $233.8K total payments, HHI 164
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Neos Therapeutics, LP's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Neos Therapeutics, LP.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Neos Therapeutics, LP.
Showing 6 of 1,924 companies with CMS-reported payment data.
Acist Medical Systems, Inc.
$163.3K 644 recipients
Compare payment profiles
Avertix Medical, Inc
$164.0K 25 recipients
Compare payment profiles
Fresenius USA Manufacturing, Inc.
$163.1K 24 recipients
Compare payment profiles
Lumendi LLC
$164.6K 83 recipients
Compare payment profiles
Resmed Corp
$164.6K 1,167 recipients
Compare payment profiles
Put this to use
Neos Therapeutics, LP ranks #1061 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Neos Therapeutics, LP. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.